Effect of the duration between total body irradiation and stem cell infusion on the outcome of allogeneic transplantation with myeloablative conditioning

Yu Akahoshi, Shinichi Kako, Hirofumi Nakano, Tomotaka Ugai, Hidenori Wada, Ryoko Yamasaki, Yuko Ishihara, Koji Kawamura, Kana Sakamoto, Miki Sato, Masahiro Ashizawa, Kiriko Terasako-Saito, Shun Ichi Kimura, Misato Kikuchi, Hideki Nakasone, Rie Yamazaki, Junya Kanda, Junji Nishida, Yoshinobu Kanda

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: Limited data are available on the effect of how cyclophosphamide (CY) and total body irradiation (TBI) are administered. We analyzed the effect of the interval from TBI to hematopoietic stem cell transplantation (HSCT) on the outcome of HSCT. Methods: Adult patients who underwent HSCT using myeloablative conditioning consisting of TBI and CY were retrospectively analyzed. They were divided into three groups according to the duration between the start of TBI and HSCT (Group A: 2–4 days, Group B: 5–8 days, Group C: 9–10 days). Results: Seventy-five adult patients were included. The 3-year overall survival rate was 56, 47, and 77% in Groups A, B, and C, respectively (P = 0.14). Similarly, there was no significant difference among the three groups with respect to progression-free survival (57, 47, and 72%, P = 0.17), relapse rate (32, 37, and 16%, P = 0.29), or non-relapse mortality (8, 14, and 12%, P = 0.81). In addition, we observed no significant difference among the three groups with respect to the incidence of grade II–IV acute graftversus-host disease (GVHD) (31, 47, and 32%, respectively, P = 0.56) and that of chronic GVHD (23, 23, and 22%, respectively, P = 0.97). Discussion and conclusion: Although recipient immune system at HSCT might be affected by the timing of TBI, the duration between the start of TBI and HSCT did not influence the outcome of HSCT using myeloablative conditioning with TBI and CY.

Original languageEnglish
Pages (from-to)410-415
Number of pages6
JournalHematology
Volume20
Issue number7
DOIs
Publication statusPublished - 2015 Jan 1
Externally publishedYes

Fingerprint

Whole-Body Irradiation
Hematopoietic Stem Cell Transplantation
Homologous Transplantation
Stem Cells
Cyclophosphamide
Disease-Free Survival
Immune System
Survival Rate
Recurrence
Mortality
Incidence

Keywords

  • Cyclophosphamide
  • Graft-versus-host disease
  • Hematopoietic stem cell transplantation
  • Total body irradiation
  • Transplantation conditioning

ASJC Scopus subject areas

  • Hematology

Cite this

Effect of the duration between total body irradiation and stem cell infusion on the outcome of allogeneic transplantation with myeloablative conditioning. / Akahoshi, Yu; Kako, Shinichi; Nakano, Hirofumi; Ugai, Tomotaka; Wada, Hidenori; Yamasaki, Ryoko; Ishihara, Yuko; Kawamura, Koji; Sakamoto, Kana; Sato, Miki; Ashizawa, Masahiro; Terasako-Saito, Kiriko; Kimura, Shun Ichi; Kikuchi, Misato; Nakasone, Hideki; Yamazaki, Rie; Kanda, Junya; Nishida, Junji; Kanda, Yoshinobu.

In: Hematology, Vol. 20, No. 7, 01.01.2015, p. 410-415.

Research output: Contribution to journalArticle

Akahoshi, Y, Kako, S, Nakano, H, Ugai, T, Wada, H, Yamasaki, R, Ishihara, Y, Kawamura, K, Sakamoto, K, Sato, M, Ashizawa, M, Terasako-Saito, K, Kimura, SI, Kikuchi, M, Nakasone, H, Yamazaki, R, Kanda, J, Nishida, J & Kanda, Y 2015, 'Effect of the duration between total body irradiation and stem cell infusion on the outcome of allogeneic transplantation with myeloablative conditioning', Hematology, vol. 20, no. 7, pp. 410-415. https://doi.org/10.1179/1607845414Y.0000000217
Akahoshi, Yu ; Kako, Shinichi ; Nakano, Hirofumi ; Ugai, Tomotaka ; Wada, Hidenori ; Yamasaki, Ryoko ; Ishihara, Yuko ; Kawamura, Koji ; Sakamoto, Kana ; Sato, Miki ; Ashizawa, Masahiro ; Terasako-Saito, Kiriko ; Kimura, Shun Ichi ; Kikuchi, Misato ; Nakasone, Hideki ; Yamazaki, Rie ; Kanda, Junya ; Nishida, Junji ; Kanda, Yoshinobu. / Effect of the duration between total body irradiation and stem cell infusion on the outcome of allogeneic transplantation with myeloablative conditioning. In: Hematology. 2015 ; Vol. 20, No. 7. pp. 410-415.
@article{51ea403b957b49809f8a9a74e625a331,
title = "Effect of the duration between total body irradiation and stem cell infusion on the outcome of allogeneic transplantation with myeloablative conditioning",
abstract = "Objectives: Limited data are available on the effect of how cyclophosphamide (CY) and total body irradiation (TBI) are administered. We analyzed the effect of the interval from TBI to hematopoietic stem cell transplantation (HSCT) on the outcome of HSCT. Methods: Adult patients who underwent HSCT using myeloablative conditioning consisting of TBI and CY were retrospectively analyzed. They were divided into three groups according to the duration between the start of TBI and HSCT (Group A: 2–4 days, Group B: 5–8 days, Group C: 9–10 days). Results: Seventy-five adult patients were included. The 3-year overall survival rate was 56, 47, and 77{\%} in Groups A, B, and C, respectively (P = 0.14). Similarly, there was no significant difference among the three groups with respect to progression-free survival (57, 47, and 72{\%}, P = 0.17), relapse rate (32, 37, and 16{\%}, P = 0.29), or non-relapse mortality (8, 14, and 12{\%}, P = 0.81). In addition, we observed no significant difference among the three groups with respect to the incidence of grade II–IV acute graftversus-host disease (GVHD) (31, 47, and 32{\%}, respectively, P = 0.56) and that of chronic GVHD (23, 23, and 22{\%}, respectively, P = 0.97). Discussion and conclusion: Although recipient immune system at HSCT might be affected by the timing of TBI, the duration between the start of TBI and HSCT did not influence the outcome of HSCT using myeloablative conditioning with TBI and CY.",
keywords = "Cyclophosphamide, Graft-versus-host disease, Hematopoietic stem cell transplantation, Total body irradiation, Transplantation conditioning",
author = "Yu Akahoshi and Shinichi Kako and Hirofumi Nakano and Tomotaka Ugai and Hidenori Wada and Ryoko Yamasaki and Yuko Ishihara and Koji Kawamura and Kana Sakamoto and Miki Sato and Masahiro Ashizawa and Kiriko Terasako-Saito and Kimura, {Shun Ichi} and Misato Kikuchi and Hideki Nakasone and Rie Yamazaki and Junya Kanda and Junji Nishida and Yoshinobu Kanda",
year = "2015",
month = "1",
day = "1",
doi = "10.1179/1607845414Y.0000000217",
language = "English",
volume = "20",
pages = "410--415",
journal = "Hematology",
issn = "1024-5332",
publisher = "Taylor and Francis Ltd.",
number = "7",

}

TY - JOUR

T1 - Effect of the duration between total body irradiation and stem cell infusion on the outcome of allogeneic transplantation with myeloablative conditioning

AU - Akahoshi, Yu

AU - Kako, Shinichi

AU - Nakano, Hirofumi

AU - Ugai, Tomotaka

AU - Wada, Hidenori

AU - Yamasaki, Ryoko

AU - Ishihara, Yuko

AU - Kawamura, Koji

AU - Sakamoto, Kana

AU - Sato, Miki

AU - Ashizawa, Masahiro

AU - Terasako-Saito, Kiriko

AU - Kimura, Shun Ichi

AU - Kikuchi, Misato

AU - Nakasone, Hideki

AU - Yamazaki, Rie

AU - Kanda, Junya

AU - Nishida, Junji

AU - Kanda, Yoshinobu

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objectives: Limited data are available on the effect of how cyclophosphamide (CY) and total body irradiation (TBI) are administered. We analyzed the effect of the interval from TBI to hematopoietic stem cell transplantation (HSCT) on the outcome of HSCT. Methods: Adult patients who underwent HSCT using myeloablative conditioning consisting of TBI and CY were retrospectively analyzed. They were divided into three groups according to the duration between the start of TBI and HSCT (Group A: 2–4 days, Group B: 5–8 days, Group C: 9–10 days). Results: Seventy-five adult patients were included. The 3-year overall survival rate was 56, 47, and 77% in Groups A, B, and C, respectively (P = 0.14). Similarly, there was no significant difference among the three groups with respect to progression-free survival (57, 47, and 72%, P = 0.17), relapse rate (32, 37, and 16%, P = 0.29), or non-relapse mortality (8, 14, and 12%, P = 0.81). In addition, we observed no significant difference among the three groups with respect to the incidence of grade II–IV acute graftversus-host disease (GVHD) (31, 47, and 32%, respectively, P = 0.56) and that of chronic GVHD (23, 23, and 22%, respectively, P = 0.97). Discussion and conclusion: Although recipient immune system at HSCT might be affected by the timing of TBI, the duration between the start of TBI and HSCT did not influence the outcome of HSCT using myeloablative conditioning with TBI and CY.

AB - Objectives: Limited data are available on the effect of how cyclophosphamide (CY) and total body irradiation (TBI) are administered. We analyzed the effect of the interval from TBI to hematopoietic stem cell transplantation (HSCT) on the outcome of HSCT. Methods: Adult patients who underwent HSCT using myeloablative conditioning consisting of TBI and CY were retrospectively analyzed. They were divided into three groups according to the duration between the start of TBI and HSCT (Group A: 2–4 days, Group B: 5–8 days, Group C: 9–10 days). Results: Seventy-five adult patients were included. The 3-year overall survival rate was 56, 47, and 77% in Groups A, B, and C, respectively (P = 0.14). Similarly, there was no significant difference among the three groups with respect to progression-free survival (57, 47, and 72%, P = 0.17), relapse rate (32, 37, and 16%, P = 0.29), or non-relapse mortality (8, 14, and 12%, P = 0.81). In addition, we observed no significant difference among the three groups with respect to the incidence of grade II–IV acute graftversus-host disease (GVHD) (31, 47, and 32%, respectively, P = 0.56) and that of chronic GVHD (23, 23, and 22%, respectively, P = 0.97). Discussion and conclusion: Although recipient immune system at HSCT might be affected by the timing of TBI, the duration between the start of TBI and HSCT did not influence the outcome of HSCT using myeloablative conditioning with TBI and CY.

KW - Cyclophosphamide

KW - Graft-versus-host disease

KW - Hematopoietic stem cell transplantation

KW - Total body irradiation

KW - Transplantation conditioning

UR - http://www.scopus.com/inward/record.url?scp=84939155899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939155899&partnerID=8YFLogxK

U2 - 10.1179/1607845414Y.0000000217

DO - 10.1179/1607845414Y.0000000217

M3 - Article

C2 - 25437012

AN - SCOPUS:84939155899

VL - 20

SP - 410

EP - 415

JO - Hematology

JF - Hematology

SN - 1024-5332

IS - 7

ER -